Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Nov;28(5):648–653. doi: 10.1128/aac.28.5.648

Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans.

M J Humphrey, S Jevons, M H Tarbit
PMCID: PMC176350  PMID: 3004323

Abstract

The pharmacokinetic profile of UK-49,858 (fluconazole), a novel triazole antifungal agent which is being developed for oral and intravenous use, was determined in mice, rats, dogs, and humans. Comparative data following oral and intravenous administration showed that bioavailability was essentially complete in all four species. Peak concentrations in plasma of drug normalized to a 1-mg/kg dose level following oral administration, were relatively high: 0.7, 0.6, 1.1, and 1.4 micrograms/ml in mice, rats, dogs, and humans, respectively. The volumes of distribution ranged between 1.1 liter/kg in mice and 0.7 liter/kg in humans, which are approximate to the values for total body water. Whole body autoradiography studies in mice following intravenous administration of [14C]UK-49,858 demonstrated that the drug was evenly distributed throughout the tissues, including the central nervous system and the gastrointestinal tract. Plasma protein binding was low (11 to 12%) in all species. Marked species differences were observed in elimination half-lives, with mean values of 4.8, 4.0, 14, and 22 h in mice, rats, dogs, and humans, respectively. The major route of elimination of the drug was renal clearance, with about 70% of the dose being excreted unchanged in the urine in each species. Studies with [14C]UK-49,858 on metabolism and excretion (intravenous and oral) in mice and dogs showed that about 90% of the dose was recovered as unchanged drug in urine and feces, confirming the metabolic stability of the drug. This pharmacokinetic profile is markedly different from that of imidazole antifungal drugs and undoubtedly contributes to the excellent efficacy of UK-49,858 in vivo.

Full text

PDF
648

Images in this article

651Image
on p.651

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Borelli D., Bran J. L., Fuentes J., Legendre R., Leiderman E., Levine H. B., Restrepo A., Stevens D. A. Ketoconazole, an oral antifungal: laboratory and clinical assessment of imidazole drugs. Postgrad Med J. 1979 Sep;55(647):657–661. doi: 10.1136/pgmj.55.647.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Brass C., Galgiani J. N., Blaschke T. F., Defelice R., O'Reilly R. A., Stevens D. A. Disposition of ketoconazole, an oral antifungal, in humans. Antimicrob Agents Chemother. 1982 Jan;21(1):151–158. doi: 10.1128/aac.21.1.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Daneshmend T. K., Warnock D. W. Clinical pharmacokinetics of systemic antifungal drugs. Clin Pharmacokinet. 1983 Jan-Feb;8(1):17–42. doi: 10.2165/00003088-198308010-00002. [DOI] [PubMed] [Google Scholar]
  4. Daneshmend T. K., Warnock D. W., Turner A., Roberts C. J. Pharmacokinetics of ketoconazole in normal subjects. J Antimicrob Chemother. 1981 Oct;8(4):299–304. doi: 10.1093/jac/8.4.299. [DOI] [PubMed] [Google Scholar]
  5. Deresinski S. C., Lilly R. B., Levine H. B., Galgiani J. N., Stevens D. A. Treatment of fungal meningitis with miconazole. Arch Intern Med. 1977 Sep;137(9):1180–1185. [PubMed] [Google Scholar]
  6. Duhm B., Medenwald H., Puetter J., Maul W., Patzschke K., Wegner L. A. The pharmacokinetics of clotrimazole 14C. Postgrad Med J. 1974 Jul;50 (Suppl 1):13–16. [PubMed] [Google Scholar]
  7. Fisher J. F., Duma R. J., Markowitz S. M., Shadomy S., Espinel-Ingroff A., Chew W. H. Therapeutic failures with miconazole. Antimicrob Agents Chemother. 1978 Jun;13(6):965–968. doi: 10.1128/aac.13.6.965. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Heel R. C., Brogden R. N., Pakes G. E., Speight T. M., Avery G. S. Miconazole: a preliminary review of its therapeutic efficacy in systemic fungal infections. Drugs. 1980 Jan;19(1):7–30. doi: 10.2165/00003495-198019010-00002. [DOI] [PubMed] [Google Scholar]
  9. Heel R. C., Brogden R. N., Speight T. M., Avery G. S. Econazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 1978 Sep;16(3):177–201. doi: 10.2165/00003495-197816030-00001. [DOI] [PubMed] [Google Scholar]
  10. Richardson K., Brammer K. W., Marriott M. S., Troke P. F. Activity of UK-49,858, a bis-triazole derivative, against experimental infections with Candida albicans and Trichophyton mentagrophytes. Antimicrob Agents Chemother. 1985 May;27(5):832–835. doi: 10.1128/aac.27.5.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ritter W., Patzschke K., Krause U., Stettendorf S. Pharmacokinetic fundamentals of vaginal treatment with clotrimazole. Chemotherapy. 1982;28 (Suppl 1):37–42. doi: 10.1159/000238150. [DOI] [PubMed] [Google Scholar]
  12. Sawyer P. R., Brogden R. N., Pinder R. M., Speight T. M., Avery Clotrimazole: a review of its antifungal activity and therapeutic efficacy. Drugs. 1975;9(6):424–447. doi: 10.2165/00003495-197509060-00003. [DOI] [PubMed] [Google Scholar]
  13. Street H. V., Vycudilik W., Machata G. Gas-liquid chromatography of submicrogram amounts of drugs. V. Preparation of low-activity packed columns and their application to the toxicological analysis of underivatized polar drugs in the low nanogram range. J Chromatogr. 1979 Jan 11;168(1):117–124. doi: 10.1016/s0021-9673(00)80699-8. [DOI] [PubMed] [Google Scholar]
  14. ULLBERG S. Studies on the distribution and fate of S35-labelled benzylpenicillin in the body. Acta Radiol Suppl. 1954;118:1–110. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES